Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDI Calidi Biotherapeutics	$5.86 +10.8%	$5.50	$2.43 ▼ $46.68	$17.73M	1.15	645,531 shs	154,660 shs
ERYP ERYTECH Pharma	$3.10	$4.66	$0.30 ▼ $1.47	$105.77M	2.69	93,510 shs	N/A
IKT Inhibikase Therapeutics	$1.71 -2.3%	$1.80	$1.12 ▼ $4.20	$130.10M	0.9	195,907 shs	131,136 shs
PLX Protalix BioTherapeutics	$1.61 -1.8%	$1.49	$0.82 ▼ $3.10	$128.17M	-0.21	846,585 shs	936,917 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDI Calidi Biotherapeutics	+4.96%	-27.03%	-42.00%	+10.21%	-74.81%
ERYP ERYTECH Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
IKT Inhibikase Therapeutics	+15.89%	-2.78%	-5.41%	-17.45%	+32.58%
PLX Protalix BioTherapeutics	+1.86%	+15.49%	+16.31%	-1.80%	+56.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDI Calidi Biotherapeutics	0.0931 of 5 stars	0.0	2.0	0.0	0.0	0.6	0.0	0.6
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	1.9516 of 5 stars	3.3	3.0	0.0	0.0	1.1	0.0	1.3
PLX Protalix BioTherapeutics	3.6253 of 5 stars	3.5	3.0	0.0	0.0	3.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDI Calidi Biotherapeutics	0.00	N/A	N/A	N/A
ERYP ERYTECH Pharma	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	280.12% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	831.68% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	($2.32) per share	N/A
ERYP ERYTECH Pharma	$32.66M	3.24	N/A	N/A	$0.80 per share	3.88
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PLX Protalix BioTherapeutics	$59.76M	2.14	$0.09 per share	17.80	$0.47 per share	3.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
ERYP ERYTECH Pharma	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	5.19	N/A	-21.03%	-30.89%	-11.74%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
ERYP ERYTECH Pharma	0.32	3.65	3.65
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDI Calidi Biotherapeutics	12.53%
ERYP ERYTECH Pharma	1.09%
IKT Inhibikase Therapeutics	3.81%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
CLDI Calidi Biotherapeutics	6.70%
ERYP ERYTECH Pharma	1.94%
IKT Inhibikase Therapeutics	7.30%
PLX Protalix BioTherapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDI Calidi Biotherapeutics	38	3.03 million	20.04 million	N/A
ERYP ERYTECH Pharma	49	34.12 million	33.46 million	Not Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable

ERYP, CLDI, IKT, and PLX Headlines

Recent News About These Companies

Protalix BioTherapeutics, Inc. (NYSE:PLX) Director Aharon Schwartz Buys 129,000 Shares

August 13 at 5:41 AM | insidertrades.com

Head-To-Head Analysis: Protalix BioTherapeutics (NYSE:PLX) & AlloVir (NASDAQ:ALVR)

August 10 at 3:23 AM | americanbankingnews.com

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

August 7, 2025 | prnewswire.com

Protalix Lawsuit Dismissed After Bylaws Amendment

August 1, 2025 | tipranks.com

Protalix BioTherapeutics Names Gilad Mamlok Chief Financial Officer

July 21, 2025 | marketwatch.com

Protalix BioTherapeutics Names SVP and CFO

July 21, 2025 | contractpharma.comC

Protalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

July 21, 2025 | finanznachrichten.de

Protalix BioTherapeutics welcomes new finance chief

July 21, 2025 | proactiveinvestors.com

PLX | Protalix BioTherapeutics Inc. Annual Cash Flow Statement ...

July 10, 2025 | marketwatch.com

Protalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitution

June 30, 2025 | proactiveinvestors.com

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025 | finance.yahoo.com

PLX: First Quarter Results

May 13, 2025 | msn.com

Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges

May 10, 2025 | uk.investing.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 10, 2025 | finanznachrichten.de

Protalix BioTherapeutics Q1 Earnings Preview

May 10, 2025 | msn.com

1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings Preview

May 10, 2025 | benzinga.com

Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth

May 9, 2025 | proactiveinvestors.com

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 9, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP, CLDI, IKT, and PLX Company Descriptions

Calidi Biotherapeutics NYSE:CLDI

$5.86 +0.57 (+10.78%)

Closing price 04:00 PM Eastern

Extended Trading

$5.75 -0.11 (-1.88%)

As of 07:59 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Inhibikase Therapeutics NYSE:IKT

$1.71 -0.04 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$1.71 0.00 (0.00%)

As of 06:33 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Protalix BioTherapeutics NYSE:PLX

$1.61 -0.03 (-1.83%)

Closing price 04:00 PM Eastern

Extended Trading

$1.63 +0.02 (+1.18%)

As of 07:35 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time